Arbor Biotechnologies is at the forefront of developing next-generation gene editing technologies aimed at treating genetic diseases. The company has created a diverse toolbox of novel gene editors that can address the root causes of various genetic disorders. Their approach includes multiple platforms for gene editing, such as knockdown techniques, precision (RT) editing, and nuclease excision, which allow for targeted modifications of the human genome. By leveraging advanced delivery methods like lipid nanoparticles (LNPs) and adeno-associated viruses (AAVs), Arbor aims to provide durable, one-time therapies that can significantly improve patient outcomes, particularly in liver and central nervous system (CNS) diseases.

The company’s pipeline includes several promising programs targeting conditions such as primary hyperoxaluria and transthyretin amyloidosis, with a focus on high unmet medical needs. Arbor's proprietary discovery engine utilizes sophisticated methods, including AI and machine learning, to optimize their gene editing technologies and enhance their therapeutic capabilities. By continuously evolving their editing tools and focusing on a multi-step drug development approach, Arbor Biotechnologies is positioned to revolutionize the treatment landscape for genetic diseases, offering tailored solutions that can address a wide range of conditions.

United States

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Arbor Biotechnologies

Company Details